ADRB3 and heart failure: Although mirabegron is used at nanomolar concentrations (Silva et al., 2017), the existence of receptor desensitization has not been rule out, and considering the results presented herein, further understanding and characterization of the mechanisms involved in β3AR desensitization would allow overcoming potential limitations that chronic use of agonists may bring in a long-term therapy of heart failure or overactive bladder syndrome.